Pliant Therapeutics, Inc. (PLRX)

NASDAQ: PLRX · IEX Real-Time Price · USD
15.01
-0.93 (-5.83%)
At close: Sep 22, 2023, 4:00 PM
15.31
+0.30 (2.00%)
After-hours: Sep 22, 2023, 6:16 PM EDT
-5.83%
Market Cap 898.11M
Revenue (ttm) 5.03M
Net Income (ttm) -144.42M
Shares Out 59.83M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 523,628
Open 15.97
Previous Close 15.94
Day's Range 14.98 - 15.99
52-Week Range 14.98 - 36.64
Beta 1.25
Analysts Strong Buy
Price Target 48.36 (+222.19%)
Earnings Date Nov 7, 2023

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated wit... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 2020
Employees 155
Stock Exchange NASDAQ
Ticker Symbol PLRX
Full Company Profile

Financial Performance

In 2022, PLRX's revenue was $9.69 million, an increase of 27.91% compared to the previous year's $7.57 million. Losses were -$123.32 million, 26.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PLRX stock is "Strong Buy." The 12-month stock price forecast is $48.36, which is an increase of 222.19% from the latest price.

Price Target
$48.36
(222.19% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutic...

8 days ago - GlobeNewsWire

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutic...

12 days ago - GlobeNewsWire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

24 days ago - GlobeNewsWire

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

26 days ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegrast in patients with PSC expected in the third quarter of 2023 Initiation of P...

6 weeks ago - GlobeNewsWire

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

6 weeks ago - GlobeNewsWire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitis Presentations highlight preclinical and clinical advancements of bexotegrast prog...

3 months ago - GlobeNewsWire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

4 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

4 months ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Positive long-term data from INTEGRIS-IPF 320 mg dose group at 24-weeks demonstrated bexotegrast was well tolerated with durable improvement shown across multiple measures

4 months ago - GlobeNewsWire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment  with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80%  relative to standar...

5 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutic...

5 months ago - GlobeNewsWire

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

Posters include data across biomarker, translation and clinical studies supporting development of bexotegrast (PLN-74809), a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF

6 months ago - GlobeNewsWire

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose Recent independent Data Safe...

6 months ago - GlobeNewsWire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

- Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC

7 months ago - GlobeNewsWire

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutic...

7 months ago - GlobeNewsWire

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Phase 1 clinical study initiation expected in the second quarter of 2023 Phase 1 clinical study initiation expected in the second quarter of 2023

8 months ago - GlobeNewsWire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

8 months ago - GlobeNewsWire

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Patients with this condition have difficulty breathing due to a buildup of lung scar tissue. They have difficulty breathing due to built-up scar tissue in their lungs.

8 months ago - MarketBeat

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

8 months ago - GlobeNewsWire

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

8 months ago - GlobeNewsWire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

8 months ago - GlobeNewsWire

Pliant Therapeutics shares rally 75%

Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibro...

8 months ago - Market Watch

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Bexotegrast demonstrated statistically significant increase  in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups

8 months ago - GlobeNewsWire

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics...

9 months ago - GlobeNewsWire